All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit the Lymphoma Coalition.
An expert panel hosted by
Sequencing immune-based therapies in B-cell malignancies
with Ulric Jäger, Sagar Lonial, and Krina Patel
Saturday, June 15 | 18:00-19:30 CEST
Register nowThis independent education activity is sponsored by Bristol Myers Squibb. All content is developed independently by the faculty. Funders are allowed no direct influence on the content of this activity.
The Lymphoma Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the Lymphoma Hub cannot guarantee the accuracy of translated content. The Lymphoma Hub and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
Bookmark this article
On Monday 3rd April at AACR 2017, during the “MS.CL10.01 - Clinical Biomarkers” session, John Rossi from Kite Pharma, Santa Monica, CA, gave a talk titled: “Polyfunctional anti-CD19 CAR T cells determined by single-cell multiplex proteomics associated with clinical activity in patients with advanced non-Hodgkin’s lymphoma.”
Rossi began the talk by providing some background on CD19 specific Chimeric Antigen Receptor (CAR) T-cell therapy:
The talk then discussed how CAR T-cell polyfunctionality is quantified:
Rossi then went on to outline the recent results published by Kochenderfer et al. in the Journal of Clinical Oncology (NCT00924326), which found that anti-CD19 CAR T-cell therapy results in durable tumor regression in relapsed NHL patients:
Following this, Rossi presented data indicating that pre-infusion single-cell CAR PSI and CAR PEAK levels in vivo and polyfunctional strength are significantly associated with objective response. However, pre-infusion product PSA is not significantly associated with expansion of CAR T-cells.
Before concluding the talk, John Rossi also presented data which indicated that IL-17a, IFN-γ, IL-8, IL-5, and MIP-1α drive CD4 polyfunctionality in responders.
Understanding your specialty helps us to deliver the most relevant and engaging content.
Please spare a moment to share yours.
Please select or type your specialty
Subscribe to get the best content related to lymphoma & CLL delivered to your inbox